A B S T R A C T Rosette formation with unsensitized sheep erythrocytes is a characteristic of human thymus dependent lymphocytes. Release of glycopeptides from the sheep erythrocyte by trypsin reduces rosette formation. These tryptic glycopeptides inhibit rosette formation by untrypsinized sheep erythrocytes; this suggests that rosetting is mediated by erythrocyte surface glycopeptides. To investigate the molecular nature of this interaction, we examined the abilities of various model compounds to act as haptenic inhibitors of rosette formation. Inhibition is given by glycopeptides bearing oligosaccharide units rich in sialic acid, galactose, Nacetylglucosamine, and mannose linked to asparagine residues through glycosylamine bonds. Among compounds tested, fetuin glycopeptide is most effective, but human transferrin glycopeptide and human erythrocyte glycopeptide I also inhibit rosette formation. Other compounds including human erythrocyte glycopeptide II, human IgG glycopeptide, lacto-N-neotetraose, 3'-and 6'-sialyllactose show no significant inhibition. Neither sialic acid, galactose, mannose, nor N-acetylglucosamine alone inhibits rosette formation. Stepwise degradation of fetuin glycopeptide establishes the galactose residues as important determinants of inhibitory activity.
INTRODUCTION
The immune system in higher organisms is composed of many lymphocyte subpopulations. In the human, one subpopulation of lymphocytes interacts in vitro with unsensitized sheep -erythrocytes to form structures termed "rosettes" (1) (2) (3) (4) . Rosettes ( Fig. 1 ) consist of a central lymphocyte surrounded by a cluster of attached sheep erythrocytes. Evidence suggests that the human rosette-forming cell is the thymus-dependent (T) lymphocyte' (5, 6 ) and rosette formation is at present the most commonly used method for identifying this important lymphocyte subpopulation. Indeed, the technique has been widely applied to assess the normal distribution of T lymphocytes, as well as their participation in various pathological states. Despite the usefulness of rosette formation as a clinical tool and its potential importance for further understanding basic mechanisms of human immunity, it remains a poorly understood phenomenon. The present studies were undertaken to investigate the molecular basis for rosette formation. FIGURE 1 Rosette formation between human peripheral blood lymphocytes and sheep erythrocytes. Rosette formation was carried out as described in Methods. Rosettes were photographed using interference phase microscopy (X 1,600).
The findings indicate that rosette formation is mediated through the interaction of sheep erythrocyte surface glycopeptides with receptor sites on the lymphocyte membrane. To examine structural features of this interaction we have studied the effect of model compounds upon rosette formation. METHODS Fetuin (B grade), pronase (B grade), and trypsin (A grade), were purchased from Calbiochem, San Diego, Calif.
Galactose dehydrogenase from Pseudomonas fluorescens (1.1.1.48) and bovine serum albumin were obtained from Sigma Chemical Co., St. Louis, Mo. HEM Laboratories, Rockville, Md. provided fetal calf serum, and human AB serum was purchased from Grand Island Biological Co., Grand Island, N. Y. Medium-199 came from Microbiological Associates, Bethesda, Md. Pharmacia Fine Chemicals Inc., Piscataway, N. J. was the source for ficoll and dextran T250 (mol wt 250,000).
[8H] Sodium borohydride (700 mCi/mmol) and NCS solubilizer were supplied by Amersham/Searle Corp., Arlington Heights, Ill. Winthrop Laboratories, New York provided sodium diatrizoate (Hypaque sodium, 50% wt/vol), and Hydromix scintillation counting cocktail was purchased from Yorktown Research Inc., S. Hackensack, N. J. Cell preparation. Venous blood was obtainedfromhealthy young adults. Lymphocytes were isolated from defibrinated whole blood by dextran sedimentation of the erythrocytes followed by isopyknic centrifugation of the leukocyte-rich supernate on a Ficoll-Hypaque mixture (7) . Resultant cell preparations consisted of greater than 90%o lymphocytes.
Lymphocytes from six untreated patients with chronic lymphatic leukemia (CLL) were purified in the same fashion.
Spleens were removed from 250-300-g Walter Reed strain guinea pigs sacrificed by cervical dislocation. Cell suspensions were prepared by pressing the spleens through wire mesh followed by filtration through gauze and isopyknic centrifugation on Ficoll-Hypaque. (12) were prepared from outdated bank blood by the methods described by Presant and Kornfeld (12) . The purified human erythrocyte glycopeptide I effectively inhibited agglutination of human erythrocytes by E-phytopoThe term "fetuin glycopeptide I" is used in this paper to refer to the N-glycosidically linked glycopeptide of fetuin, the structure of which is given in Table I . This designation is used to distinguish this structure from theb-glycosidically linked fetuin glycopeptide recently described by Spiro and Bhoyroo ( 11 ) .
hemagglutinin from Phaseolus vulgaris (8) while glycopeptide II inhibited the erythrocyte agglutination caused by crude extracts of Agaricus bisporus (12) . Lacto-N-neotetraose and 3'-and 6'-sialyllactose were kindly provided by Dr. K. Joseph. Purified human transferrin glycopeptide (13) was donated by Dr. M. Jett, and the purified human IgG glycopeptide (14, 15) was a gift from Dr. R. Kornfeld, who also provided asialo-agalacto fetuin glycopeptide I produced from fetuin glycopeptide I by mild acid hydrolysis (16) followed by treatment with jackbean j3-galactosidase (17) . Gas chromatographic analysis by Dr. Kornfeld indicated that the derivative compound retained less than 15% of the sialic acid and only 25% of the galactose but all of the mannose and N-acetyl glucosamine of the parent compound.
Degradation of fetuin glycopeptide. Sialic acid was removed from native fetuin or from fetuin glycopeptide I by hydrolysis in 0.05 N HSO4 at 80'C for 1 h (16). After neutralization with NaOH, the native fetuin was dialyzed to remove salt and free sialic acid, while the glycopeptide was desalted and freed from sialic acid by passage over a Sephadex G-25 column. These procedures regularly resulted in the release of greater than 95% of sialic acid residues from these compounds.
Galactose was removed from asialofetuin by periodate oxidation followed by sodium borohydride reduction and mild acid hydrolysis (18) . Asialofetuin, 12 mg/ml in 0.05 M sodium acetate, pH 4.5, was reacted with 0.01 M sodium metaperiodate at 4°C for 6 or 24 h in the dark. The reaction was terminated with a 2.5-fold molar excess of ethylene glycol, and the mixture then dialyzed against distilled water. The salt-free material was reduced with 0.15 M sodium borohydride in 0.15 M sodium borate buffer, pH 8.0, for 16 h at 4°C. The pH was adjusted to 5.0 using acetic acid and the preparation again dialyzed. Acetal bonds were cleaved by heating at 80°C for 60 min in 0.05 N H2S04. The sample was neutralized with NaOH, dialyzed, then lyophilized. This procedure resulted in release of approximately 80-90% of galactose residues from asialofetuin.
The N-glycosidic glycopeptides were prepared from both asialofetuin and asialo-agalacto-fetuin by pronase digestion and gel filtration as described above.
Preparation of radiolabeled fetuin glycopeptide I. Fetuin glycopeptide I was labeled in the terminal sialic acid residues with tritium using the method of Van Lenten and Ashwell (19 Parallel incubations without cells were carried out to correct for nonspecific binding to the glass tubes. After incuba-tion, cells were harvested by washing them twice with 5 ml 0.9% NaCl-0.01 M NaHCO8. The cell pellets were dissolved in 0.5 ml NCS, transferred to counting vials containing 10 ml Hydromix, and counted in a Beckman LS-345 Liquid Scintillation System (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.).
For studies of [3H]fetuin glycopeptide I binding to sheep erythrocyte membranes, 10-200 ,ug of membrane protein was incubated with varying concentrations of radiolabeled glycopeptide in 15-ml thick-walled glass centrifuge tubes (Corex) that had been presoaked in albumin. After incubation, membranes were washed twice with 5 ml of cold bicarbonatebuffered saline and collected by centrifugation at 45,000 g for 15 min. The washed membranes were dissolved in NCS and prepared for liquid scintillation counting as described above.
Chemical determinations. Sialic acid was assayed by the method of Warren (20) after hydrolysis in 1 N HCl for 75 s at 1000C (21) . Total hexose was measured by the phenolsulfuric method scaled down to one-fifth volume (22) . Galactose was assayed enzymatically using galactose dehydrogenase (23 Fig. 2 , the inhibitory effect of trypsin is both concentration and time dependent.
Effect of trypsin-released glycopeptides on rosette formation. We considered that trypsin might release erythrocyte surface receptors for rosette formation, and tested the trypsin-released glycopeptides for their ability Table I summarize the ability of a number of glycopeptides, oligosaccharides, and simple sugars to act as inhibitors of rosette formation. In addition, Table I illustrates important structural features of the model compounds tested. Fetuin glycopeptide I was the most effective inhibitory compound, but significant in-'A modification of the Thrombo-Wellcotest (Burroughs Wellcome & Co., Greenville, N. C.) for fibrinogen degradation products (26) was employed to assay this preparation for residual proteolytic activity. By this technique, using purified human fibrinogen as substrate, an amount of glycopeptide giving 50% inhibition of rosette formation contained proteolytic activity equivalent to no more than 0.1 pg/ml trypsin. Because of its availability, further studies were carried out with fetuin glycopeptide I. When this compound was hydrolyzed to its component monosaccharides by heating in a boiling water bath for 6 h in the presence of 2 N H2SO4 in a sealed vial (18) and then neutralized, its inhibitory activity was abolished. By contrast, the inhibitory activity was not affected by treatment with 0.1 N NaOH under nitrogen for 24 h at 250C (18) , indicating that inhibition was not due to the presence of intact O-glycosidically linked fetuin glycopeptide (11) contaminating the fetuin glycopeptide I. Finally, fetuin glycopeptide I, 100 nmol/ml, had no effect upon lymphocyte viability as assessed by trypan blue exclusion.
Fetuin comprises the major a-globulin of fetal calf serum (31 (33) Table IV demonstrate a correlation between rosette formation and fetuin glycopeptide I binding. Competitive binding studies. These studies were undertaken to investigate the possibility that fetuin glycopeptide I and the sheep erythrocyte surface structure responsible for rosette formation might bind to the same lymphocyte receptor. Results of a typical study are illustrated in Fig. 5 . Binding of radiolabeled fetuin glycopeptide I to lymphocytes was competitively inhibited in the presence of sheep erythrocyte tryptic glycopeptides. DISCUSSION These studies indicate that rosette formation between human lymphocytes and sheep erythrocytes is mediated through the interaction of trypsin-sensitive sheep cellsurface glycoproteins with the lymphocyte membrane. Glycopeptide material solubilized from the sheep cell surface by trypsin effectively inhibits rosette formation. Because the quantity of inhibitory material retrievable from large quantities of sheep blood was insufficient for extensive studies, we have used model compounds in haptene inhibition experiments to examine the structural nature of the sheep erythrocyte glycopeptides that participate in rosette formation.
The data in Table I demonstrate several important points. First, compounds that inhibit rosette formation share certain structural features. Thus the basic structure sialic acid ->galactose -*N-acetylglucosamine linked to a core of mannose residues is present in fetuin glycopeptide I, human transferrin glycopeptide, and human erythrocyte glycopeptide I. Second, the potency of the various inhibitors seems to be related to their content of oligosaccharide chains with this basic structure. Thus, fetuin glycopeptide I with three of these chains per molecule is a better inhibitor than the transferrin glycopeptide and the human erythrocyte glycopeptide I which contain only two (Table I ). The difference in the inhibitory activity of these latter two glycopeptides may relate to the differences in their core structures.
Further evidence supporting the importance of the core mannose residues for inhibition of rosette formation is derived from a consideration of the data in Table  I for several different oligosaccharides. Lacto-N-neotetraose and 3'-and 6'-sialyllactose share certain structural sequences with the oligosaccharide chains in fetuin, transferrin, and human erythrocyte glycopeptide I, but lack the mannose core. Lacto-N-neotetraose has a galactose > N-acetylglucosamine linkage, and 3'-and 6'-sialyllactose have sialic acid linked to galactose. The fact that none of these three compounds shows significant rosette inhibition suggests that these sequences alone are not sufficient structural determinants for this inhibition. Since these compounds lack core mannose residues, these data also suggest that the mannose core may be an important determinant for inhibition.
Further structural information has been derived from the sequential degradation of fetuin glycopeptide I (Table II) , the most potent inhibitor of rosette formation that we studied. Cleavage of the terminal sialic acid residues from the three oligosaccharide chains of this molecule resulted in a consistent increase in its ability to inhibit rosette formation. This finding is of interest in light of the fact that several investigators have noted enhancement of rosette formation by human lymphocytes when the sheep erythrocytes used had been pretreated with neuraminidase (34) (35) (36) .
Removal of the terminal sialic acid and galactose residues from fetuin glycopeptide I abolishes the effectiveness of this compound as an inhibitor of rosette formation. These data suggest that among the key determinants for inhibition of rosette formation by fetuin glycopeptide I are the galactose residues in the outer chains.
Although the galactose residues of fetuin glycopeptide I are of major importance for inhibition of rosette formation, galactose and other simple sugars are ineffective inhibitors when added alone (Table I) . Similar results have been noted with respect to the receptor sites for plant lectins (8, 37) . Furthermore, when fetuin glycopeptide I is hydrolyzed to its component monosaccharides, its inhibitory effect on rosette formation is lost.
Summarizing these structural studies, we conclude that compounds containing the basic structure sialic acid -* galactose -> N-acetylglucosamine > (mannose). are effective inhibitors of rosette formation. The galactose residues are important determinants of this inhibition.
Indirect evidence for the presence on the sheep erythrocyte surface of oligosaccharide chains structurally similar to fetuin glycopeptide I comes from recent work of Sela et al. (38) . Using affinity chromatography on fetuin covalently attached to Sepharose to fractionate sera from a variety of animal sources, these workers isolated antibodies which appeared to recognize the specific oligosaccharide sequences of fetuin. These purified immunoglobulin fractions agglutinated erythrocytes from sheep and some other mammalian species. In addition, Fletcher and Woolfolk (39) have isolated a glycoprotein antigen from sheep erythrocytes which contains molar ratios of carbohydrates similar to those ratios in fetuin. Our data (Fig. 5 ) which illustrate competitive inhibition of radiolabeled fetuin glycopeptide I binding by the sheep erythrocyte tryptic glycopeptides suggest that certain structures in both preparations can bind to the same lymphocyte surface receptor. It therefore seems likely that a structure similar to fetuin glycopeptide I is present on the sheep erythrocyte surface and may take part in rosette formation. However, the possibility remains that steric hindrance or surface charge modification may contribute to the observed effects of fetuin glycopeptide I and structurally related compounds in our system. The preincubation studies (Table III) and the binding studies with tritiated fetuin glycopeptide I (Fig. 4) indicate that compounds with this basic structure are capable of binding to the human lymphocyte surface.
There are approximately 7.5 x 108 binding sites per lymphocyte for fetuin glycopeptide I and the binding affinity, K., is 5.5 X 10' M-1. This affinity is in accord with the fragile nature of rosettes which tend to dissociate easily. The inhibitory constant, K,, for the inhibition of rosette formation by fetuin glycopeptide I, is 1.3 X 10' MW. This value is in agreement with the association constant for fetuin binding, indicating that the inhibition of rosette formation by fetuin glycopeptide I is closely related to its ability to bind to the lymphocyte surface. The latter point is strengthened by our inability to demonstrate significant interaction between fetuin glycopeptide I and sheep erythrocyte membranes.
To examine the specificity of the fetuin glycopeptidelymphocyte interaction and its relationship to rosette formation, we studied the ability of nonrosetting lymphocyte populations to bind radiolabeled fetuin glycopeptide I. Thus mononuclear cells from guinea pig spleens fail to rosette and demonstrate no saturable binding of fetuin glycopeptide I.
Our data on a group of patients with CLL emphasize that the peripheral blood lymphocytes in this disorder are heterogeneous, containing 0.5-20% rosette-forming cells. Similar results have been noted by others (38) (39) (40) (41) (42) . As shown in Table IV , there is no apparent relationship between the percentage of CLL lymphocytes that form rosettes and the absolute lymphocyte counts of these patients. The results of fetuin glycopeptide Ibinding studies in five of the six patients (Table IV) demonstrate a correlation between rosette formation by the CLL lymphocytes and the ability of these cells to bind radiolabeled glycopeptide. In two of the patients (F. C. and J. D.), 15-20% of peripheral blood lymphocytes form rosettes, and these cells bind 1.5 and 1.7 X 106 molecules per cell of fetuin glycopeptide I, respectively. By contrast, lymphocytes from patients M. T., C. V., and L. V. contain 0.5, 4.0, and 8.5% rosetteforming cells, respectively. Cells from two of these patients (M. T. and C. V.) fail to demonstrate saturable binding of fetuin glycopeptide I, while lymphocytes from L. V. bind only 300,000 molecules per cell.
The data from the binding studies using CLL lymphocytes and guinea pig spleen cells suggest that fetuin glycopeptide I binds preferentially to human rosetteforming lymphocytes. The ability to bind this compound may thus represent a specific T-cell function. Furthermore, the data on rosette inhibition and the competitive binding studies (Fig. 5) provide the possibility that fetuin glycopeptide I is bound to the lymphocyte via the same surface receptor sites which combine with sheep erythrocytes during rosette formation.
Yachnin has recently demonstrated that fetuin is able to inhibit in vitro human lymphocyte transformation in response to stimulation by various plant mitogens, antithymocyte antiserum, and allogeneic cells (43) . Furthermore, Murgita and Tomasi have reported that a-fetoprotein added in vitro to murine lymphoid cells causes suppression of specific murine T-cell-dependent functions such as allogeneic and mitogen-induced lymphocyte transformation (44) . In addition this compound can suppress development of primary and secondary antibody production by the lymphoid cells of fetal and neonatal mice (45) , perhaps through an effect on T-cell intermediates (45) . These observations suggest that lymphocyte receptor sites for fetuin and related fetal proteins such as a-fetoprotein serve important immunoregulatory functions in vivo. Additional experiments will be required to further investigate these intriguing possibilities.
